ANI Pharmaceuticals, Inc.
General ticker "ANIP" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.4B (TTM average)
ANI Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 51.3%.
Estimated limits based on current volatility of 1.7%: low 82.30$, high 85.20$
Factors to consider:
- Total employees count: 642 (+7.0%) as of 2023
- US accounted for 98.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key suppliers, Acquisition/divestiture risks, New product risks, Economic downturns and volatility, Public health crises
- Current price 15.2% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [42.17$, 71.80$]
- 2025-12-31 to 2026-12-31 estimated range: [39.44$, 68.02$]
Financial Metrics affecting the ANIP estimates:
- Negative: with PPE of 10.5 at the end of fiscal year the price was very high
- Positive: -3.60 < Operating profit margin, % of 0.09
- Positive: 18.93 < Shareholder equity ratio, % of 31.45 <= 41.86
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of -1.42
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: Inventory ratio change, % of -0.51 <= 0
- Positive: Interest expense per share per price, % of 1.68 <= 3.41
Short-term ANIP quotes
Long-term ANIP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $316.38MM | $486.82MM | $619.72MM |
| Operating Expenses | $351.67MM | $439.85MM | $619.14MM |
| Operating Income | $-35.28MM | $46.97MM | $0.58MM |
| Non-Operating Income | $-27.38MM | $-27.10MM | $-22.80MM |
| Interest Expense | $28.05MM | $26.94MM | $17.60MM |
| R&D Expense | $22.32MM | $34.29MM | $44.58MM |
| Income(Loss) | $-62.66MM | $19.87MM | $-22.21MM |
| Taxes | $-14.77MM | $1.09MM | $-3.69MM |
| Profit(Loss)* | $-47.90MM | $18.78MM | $-18.52MM |
| Stockholders Equity | $313.69MM | $432.75MM | $403.68MM |
| Inventory | $105.36MM | $111.20MM | $136.78MM |
| Assets | $760.09MM | $904.42MM | $1,283.70MM |
| Operating Cash Flow | $-31.20MM | $118.96MM | $64.02MM |
| Capital expenditure | $16.45MM | $18.51MM | $16.95MM |
| Investing Cash Flow | $-15.74MM | $-18.51MM | $-404.72MM |
| Financing Cash Flow | $-5.13MM | $67.44MM | $264.94MM |
| Earnings Per Share** | $-2.95 | $1.04 | $-0.96 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.